Free tool
Cell therapy stocks
We cover 5 companies grouped under the Cell therapy theme. The median market value in the group is $44.34M. Across the group, the median move over the past trading day is 0.00%. Price change over the past year runs from −66.5% to −15.5% across the middle 80 percent of the group, with a median of −21.9%.
Other lists in this group
SaaSAI applicationsCybersecuritySemiconductor designSemiconductor equipmentFintech softwarePayment processingEcommerce marketplacesStreaming mediaGaming softwareOncologyRare diseaseMedical devicesCell therapyDiagnosticsRegional banksAsset managementGold miningCryptocurrency and digital assetsSpecialty chemicalsAll stocks
Table
5 of 86 companies match these filters.Clear filters
| Ticker | Company | Market cap (USD) | Size | 1Y return | Next report |
|---|---|---|---|---|---|
| ATRA | Atara Biotherapeutics, Inc. | $98.77M | Micro cap | −19.61% | Nov 12, 2026 |
| INKT | MiNK Therapeutics, Inc. | $60.32M | Micro cap | −21.89% | Nov 12, 2026 |
| TVGN | Tevogen Inc. | $44.34M | Micro cap | −84.85% | Nov 13, 2026 |
| SVA.TO | Sernova Biotherapeutics Inc | $30.03M | Micro cap | −38.89% | Sep 10, 2026 |
| LGVN | Longeveron Inc. | $21.68M | Micro cap | −12.71% | Nov 4, 2026 |
Covers ~22,000 companies across the US, Europe and Asia-Pacific (ex mainland China, Hong Kong and India), refreshed nightly. Every listed stock opens as a full analysis for $9.90.